AGARWALEYE
Dr. Agarwal's Health Care Ltd.
Each stock's 10,000-path forecast, rendered as light.
Dr. Agarwal's Health Care Ltd. (AGARWALEYE) Stock Analysis & Case Study
Is AGARWALEYE a good buy? The data-driven verdict.
Dr. Agarwal's Health Care Ltd. (AGARWALEYE) trades at ₹546,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Dr. Agarwal's Health Care Ltd. (AGARWALEYE) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 117.0× earnings, ROE of 6.8%, a 59% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
AGARWALEYE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How AGARWALEYE ranks against the 2,373 companies in our screener
- AGARWALEYE's market cap of 17,318 Cr ranks in the 83rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AGARWALEYE's book value of ₹64 ranks in the 39th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AGARWALEYE's promoter holding of 32.3% ranks in the 9th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AGARWALEYE's 3-year profit (PAT) growth of 13.0% ranks in the 46th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AGARWALEYE's 3-year revenue growth of 27.0% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AGARWALEYE's debt-to-equity ratio of 0.53x is lower than 33% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is AGARWALEYE overvalued? AGARWALEYE P/E vs peers
AGARWALEYE trades at 117.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
AGARWALEYE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.5y of AGARWALEYE history (21%/yr drift, 30%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AGARWALEYE 2027 | ₹400 | ₹586 | ₹858 | +7% |
| AGARWALEYE 2028 | ₹366 | ₹628 | ₹1,078 | +15% |
| AGARWALEYE 2029 | ₹353 | ₹674 | ₹1,287 | +23% |
| AGARWALEYE 2030 | ₹336 | ₹723 | ₹1,553 | +32% |
| AGARWALEYE 2031 | ₹335 | ₹775 | ₹1,796 | +42% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AGARWALEYE goes up, or doubles?
The bull case for AGARWALEYE
- Dr. Agarwal's Health Care Ltd. is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,287.
The bear case & risks
- AGARWALEYE's P/E of 117.0x is lower than 9% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 8.5× price-to-book means most of the value is intangible/expectations, not assets on the books.
- AGARWALEYE's return on equity of 6.8% ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹353.
AGARWALEYE volatility & expected range, how bumpy is the ride?
Over the last 1.5 years AGARWALEYE compounded at 21%/year with annualized volatility of 30%. That volatility implies a 1-year 80% range of ₹400-₹858, the honest backbone behind any single price target.
AGARWALEYE price forecast, the full 60-month probability fan
AGARWALEYE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AGARWALEYE hits common targets within the simulated horizon?
Full multi-horizon detail on the AGARWALEYE price target & forecast page.
AGARWALEYE Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AGARWALEYE scores 5/8, mixed financial health.
AGARWALEYE MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy AGARWALEYE with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 27.93% | 3.6× |
| Groww | 27.89% | 3.6× |
| Dhan | 27.93% | 3.6× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 27.89% | 3.6× |
| Pocketful | 27.71% | 3.6× |
| Anand Rathi | 27.93% | 3.6× |
| Bajaj Broking | 30.00% | 3.3× |
| Share IndiaCHEAPEST | 27.58% | 3.6× |
Compare every broker on the AGARWALEYE MTF page.
About Dr. Agarwal's Health Care Ltd.: sector, index & market-cap context
Dr. Agarwal's Health Care Ltd. (AGARWALEYE) is a small-cap NSE-listed company, with a market capitalisation of ₹17,318 Cr. See more stocks on our screener.
How the AGARWALEYE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Dr. Agarwal's Health Care Ltd.'s public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AGARWALEYE analysis, FAQs
Is Dr. Agarwal's Health Care Ltd. (AGARWALEYE) a good buy?
On the numbers, Dr. Agarwal's Health Care Ltd. (AGARWALEYE) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 117.0× earnings, ROE of 6.8%, a 59% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AGARWALEYE overvalued or undervalued?
AGARWALEYE trades at 117.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the AGARWALEYE share price target for 2031?
AGARWALEYE's probability-weighted 2031 median target is ₹775, with an 80% range of ₹335-₹1,796 (10,000-path Monte-Carlo).
What is the probability AGARWALEYE doubles in 5 years?
The modelled probability of AGARWALEYE reaching ₹1,093 (2×) within 5 years is 30%.
What is the bull case for AGARWALEYE?
Dr. Agarwal's Health Care Ltd. is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in AGARWALEYE?
AGARWALEYE's P/E of 117.0x is lower than 9% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 8.5× price-to-book means most of the value is intangible/expectations, not assets on the books. AGARWALEYE's return on equity of 6.8% ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.